Lakewood-Amedex Biotherapeutics, Inc.

What they do

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing novel antimicrobial therapeutics for serious infectious diseases, including those caused by antibiotic-resistant bacteria. The lead product candidate, Nu-3 (Bisphosphocin gel formulation), is being developed as a topical antimicrobial therapy for the treatment of infected diabetic foot ulcers (iDFU). The company also continues to develop its broader antimicrobial technology platform.

Revenue drivers

• Nu-3 (Bisphosphocin gel) — Lead product candidate; currently in clinical development, no revenue generated. Potential future revenue from commercialization if approved.
• Antimicrobial technology platform — Broader platform for developing antimicrobial therapeutics; no current revenue. Future value depends on advancement of pipeline candidates.

Recent performance

For the quarter ended June 30, 2026, the company raised approximately $6.8 million in net proceeds from a Series C Convertible Preferred Stock private placement and completed listing on the Nasdaq Capital Market on April 23, 2026. In connection with the listing, all outstanding Series A and Series B Convertible Preferred Stock and convertible promissory notes automatically converted into common stock, simplifying the capital structure. On June 19, 2026, the company effected a one-for-ten reverse stock split. As of June 30, 2026, the company reported total assets of $5.0 million, total liabilities of $0.63 million, shareholder equity of $4.3 million, and cash and equivalents of $2.6 million.

Strategy

Management's primary focus has shifted from capital formation to execution of clinical development objectives, specifically advancing Nu-3 toward a Phase 2a dose-comparison clinical study. Activities include manufacturing, regulatory, and clinical planning to support the trial. The Nasdaq listing is intended to increase visibility, broaden access to public capital markets, and enhance future financing opportunities. The company also simplified its capital structure by converting preferred stock and convertible debt into common stock to reduce future financing complexity.

Risks

• Clinical development risk — Nu-3 is in clinical-stage development; there is no guarantee that the Phase 2a study will be completed successfully or that the product will receive regulatory approval.
• Capital requirements — The company expects to need additional capital to complete clinical development, pursue regulatory approvals, and support commercialization; no assurance that financing will be available on favorable terms.
• Recurring operating losses — The company has incurred recurring operating losses since inception and expects to continue incurring losses as it advances clinical development, which could strain liquidity.
• Nasdaq listing and compliance — As a newly listed public company, the company faces increased costs and compliance burdens, and may not be able to maintain listing requirements in the future.

Outlook

Management expects to continue incurring losses as it advances the clinical development of Nu-3 and other product candidates. The recent financing provides financial resources for near-term operating plans, but additional capital will be required for long-term objectives. The company is advancing preparations for the planned Phase 2a clinical study of Nu-3 in iDFU.